Related references
Note: Only part of the references are listed.2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis
Bianca Bech et al.
ANNALS OF THE RHEUMATIC DISEASES (2020)
self-reported competencies and educational needs of rheumatology nurses: Results of a national survey
Catherine Beauvais et al.
JOINT BONE SPINE (2020)
Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4)
Marc Scherlinger et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2019)
Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States
A. Teeple et al.
CURRENT MEDICAL RESEARCH AND OPINION (2019)
Patients' information and perspectives on biosimilars in rheumatology: A French nation-wide survey
Lea Frantzen et al.
JOINT BONE SPINE (2019)
Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance
Marc Scherlinger et al.
JOINT BONE SPINE (2018)
Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab
Lieke Tweehuysen et al.
ARTHRITIS & RHEUMATOLOGY (2018)
The nocebo effect challenges the non-medical infliximab switch in practice
N. W. Boone et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2018)
Biosimilars: An opportunity. Position statement of the French Rheumatology Society (SFR) and Inflammatory Rheumatic Disease Club (CRI)
Thierry Schaeverbeke et al.
JOINT BONE SPINE (2018)
Systematic switch from innovator infliximab to biosimilar infliximab in inflammatory chronic diseases in daily clinical practice: The experience of Cochin University Hospital, Paris, France
Jerome Avouac et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2018)
Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4 Six-Month Results From a Controlled Cohort Study
Lieke Tweehuysen et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Nocebos in rheumatology: emerging concepts and their implications for clinical practice
Evrydiki Kravvariti et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases
Jonathan Kay et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis Associations
Laurent Peyrin-Biroulet et al.
JOURNAL OF CROHNS & COLITIS (2017)
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
Kristin K. Jorgensen et al.
LANCET (2017)
Comparing Generic Drug Markets in Europe and the United States: Prices, Volumes, and Spending
Olivier J. Wouters et al.
MILBANK QUARTERLY (2017)
Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey
Stephen R. Chapman et al.
BMJ OPEN (2017)
Patients' Understanding and Attitudes Towards Infliximab and Etanercept Biosimilars: Result of a UK Web-Based Survey
Mohammed I. Aladul et al.
BIODRUGS (2017)
Perception of Originator Biologics and Biosimilars: A Survey Among Belgian Rheumatoid Arthritis Patients and Rheumatologists
Eline van Overbeeke et al.
BIODRUGS (2017)
A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
Bente Glintborg et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Pharmacoeconomics of Biosimilars: What Is There to Gain from Them?
Filipe C. Araujo et al.
CURRENT RHEUMATOLOGY REPORTS (2016)
The nocebo effect of drugs
Sara Planes et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2016)
What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs
Suzanne S. Dunne et al.
BMC MEDICINE (2015)
Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
Elena Nikiphorou et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
THE EVIDENCE FOR PATIENT EDUCATION IN INFLAMMATORY ARTHRITIS
H. A. Zangi
ANNALS OF THE RHEUMATIC DISEASES (2014)
Evolution of Direct Costs in the First Years of Rheumatoid Arthritis: Impact of Early versus Late Biologic Initiation - An Economic Analysis Based on the ESPOIR Cohort
Karine Chevreul et al.
PLOS ONE (2014)
The Influence of the Patient-Clinician Relationship on Healthcare Outcomes: A Systematic Review and MetaAnalysis of Randomized Controlled Trials
John M. Kelley et al.
PLOS ONE (2014)
Patients' needs and expectations with regard to rheumatology nursing care: results of multicentre focus group interviews
Yvonne van Eijk-Hustings et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database
T. Sokka et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
When words are painful: Unraveling the mechanisms of the nocebo effect
F. Benedetti et al.
NEUROSCIENCE (2007)
Share Paper
